Table 2 Sub-group meta-analysis of the HBV–HIV co-infection pooled prevalence estimation among ANC attendees
Variable | Analysis | ||||
|---|---|---|---|---|---|
number | Prevalence % (95% CI) | P value | I2 (%) (95% CI) | P het | |
Region | |||||
West Africa | 16 | 5.16 (2.67 to 8.39) REF | 92.25 (97.82 to 98.6) | P < 0.0001 | |
East Africa | 13 | 2.168 (0.830 to 4.116) | < 0.001* | 96.79(95.68 to 97.62) | P < 0.0001 |
South Africa | 2 | 2.317 (1.105 to 3.959) | < 0.001* | 78.4(6.03 to 95.03) | P = 0.0314 |
Central Africa | 7 | 2.441 (1.492 to 3.617) | < 0.001* | 88.02(77.70 to 93.57) | P < 0.0001 |
Year of publication | |||||
2004–2010 | 8 | 6.356 (3.611 to 9.811) | 91.15(84.97 to 94.79) | P < 0.0001 | |
2011–2019 | 30 | 2.252 (1.452 to 3.221) | < 0.001* | 97.15(96.56 to 97.64) | P < 0.0001 |
HIV + Cohort | |||||
Yes | 12 | 8.312 (5.806 to 11.22) | 94.90(92.69 to 96.45) | P < 0.0001 | |
No | 27 | 2.152 (1.358 to 3.125) | < 0.001* | 96.73(95.98 to 97.33) | P < 0.0001 |
Detection method | |||||
ELISA | 19 | 3.39 (2.06 to 5.047) REF | 93.80(91.64 to 95.41) | P < 0.0001 | |
RDT | 13 | 3.167 (1.484 to 5.449) | 0.2996 | 98.01(97.44 to 98.46) | P < 0.0001 |
Others | 6 | 3.323 (0.955 to 7.050) | 0.7443 | 98.89(98.46 to 99.20) | P < 0.0001 |